DCTH - Delcath Systems, Inc.

NasdaqCM - NasdaqCM Delayed Price. Currency in USD
0.005
0.000 (0.00%)
At close: 3:59PM EDT
Stock chart is not supported by your current browser
Previous Close0.005
Open0.000
Bid0.000 x 0
Ask0.000 x 0
Day's Range0.000 - 0.000
52 Week Range
Volume0
Avg. Volume25,257
Market Cap2.242M
Beta-0.71
PE Ratio (TTM)N/A
EPS (TTM)-6.503
Earnings DateMar 23, 2017 - Mar 24, 2017
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est16.00
Trade prices are not sourced from all markets
  • GlobeNewswire5 days ago

    Delcath Sponsors Looking For A Cure Ocular Melanoma Charity Event

    Delcath Systems, Inc. (DCTHD), an interventional oncology company focused on the treatment of primary and metastatic liver cancers, is proud to sponsor A Cure In Sight and its first annual Looking for a Cure 5K charity event.  A Cure in Sight is a patient advocacy group dedicated to providing patient services for ocular melanoma patients and their families. Looking for a Cure was held in Palo Alto, CA at the Byers Eye Institute on May 20, 2018. The event raised over $15,000 to support A Cure In Sight’s efforts in research, awareness and financial support programs for ocular melanoma patients.

  • GlobeNewswire11 days ago

    Delcath’s CHEMOSAT Included in German Treatment Guidelines for Melanoma Liver Metastases

    Delcath Systems, Inc. (DCTHD), an interventional oncology company focused on the treatment of primary and metastatic liver cancers, announces that the German Guidelines Program in Oncology (GGPO) has included treatment with Delcath’s CHEMOSAT® in the German national treatment guidelines for liver metastases from melanoma. This inclusion of treatment with CHEMOSAT is in the S3 Guidelines, which represents the highest level within the classification of the guidelines indicating that it is based on evidence and consensus within the German clinical community. The GGPO’s update was based on its evaluation of published data on treatment with CHEMOSAT as a loco-regional treatment for melanoma liver metastases.  Following this evaluation, and after soliciting additional feedback from the oncology community in Germany, treatment with CHEMOSAT was classified with Evidence Level 1B, indicating the second highest level of evidence.

  • GlobeNewswire13 days ago

    Delcath’s PHP Therapy Featured in Video Learning Session at the European Conference of Interventional Oncology 

    Delcath Systems, Inc. (DCTHD), an interventional oncology company focused on the treatment of primary and metastatic liver cancers, announces that the Company’s PHP Therapy was featured in a Video Learning Session presented at the Annual Meeting of the European Conference of Interventional Oncology (ECIO). Dr. M.C. Burgmans of Leiden University Medical Center (LUMC) in the Netherlands presented the training in the main auditorium session dedicated to advances in liver cancer therapies.  Dr. Burgmans presented an overview of the Percutaneous Hepatic Perfusion (PHP) procedure, discussed the therapy’s developmental history, demonstrating how to perform the procedure, as well as outlining its potential in ocular melanoma liver metastases and intrahepatic cholangiocarcinoma, and highlighting ongoing clinical research.

  • GlobeNewswire17 days ago

    Delcath Announces First Quarter 2018 Financial Results

    NEW YORK, May 10, 2018-- Delcath Systems, Inc., an interventional oncology Company focused on the treatment of primary and metastatic liver cancers, announces financial results for the quarter ended March ...

  • GlobeNewswire20 days ago

    Delcath Announces Initiation of Registrational Trial of Melphalan/HDS in Intrahepatic Cholangiocarcinoma

    Delcath Systems, Inc. (DCTHD), an interventional oncology company focused on the treatment of primary and metastatic liver cancers, announces that the Company has initiated its pivotal trial of Melphalan Hydrochloride for Injection for use with the Delcath Hepatic Delivery System (Melphalan/HDS) to treat patients with intrahepatic cholangiocarcinoma (ICC). The trial, entitled A Randomized, Controlled Study to Compare the Efficacy, Safety and Pharmacokinetics of Melphalan/HDS Treatment Given Sequentially Following Cisplatin/Gemcitabine versus Cisplatin/Gemcitabine (Standard of Care) in Patients with Intrahepatic Cholangiocarcinoma, (the ALIGN Trial) will seek to enroll approximately 295 ICC patients at approximately 40 clinical sites in the U.S. and Europe.

  • GlobeNewswire23 days ago

    Delcath to Present at the RHK Capital 2018 Disruptive Growth and Healthcare Conference

    NEW YORK, May 04, 2018-- Delcath Systems, Inc., an interventional oncology Company focused on the treatment of primary and metastatic liver cancers, announces that Jennifer K. Simpson, Ph.D., MSN, CRNP, ...

  • GlobeNewswire24 days ago

    Delcath Announces Another DSMB Recommendation for Phase 3 Focus Trial

    Delcath Systems, Inc. (DCTHD), an interventional oncology company focused on the treatment of primary and metastatic liver cancers, announces that the independent Data Safety Monitoring Board (DSMB) of the Phase 3 FOCUS clinical trial for Patients with Hepatic Dominant Ocular Melanoma has completed another review of safety data for treated patients in the trial. The FOCUS Trial is evaluating the efficacy, safety and pharmacokinetics of Melphalan/HDS versus best alternative standard of care in 240 patients with metastatic ocular melanoma (OM).

  • GlobeNewswire26 days ago

    Delcath Announces Ratio for Reverse Split Authorization

    NEW YORK, May 01, 2018-- Delcath Systems, Inc., an interventional oncology company focused on the treatment of primary and metastatic liver cancers, announces that the Company’ s Board of Directors has ...

  • GlobeNewswire2 months ago

    Delcath Announces Shareholder Approval of Consent Solicitation

    NEW YORK, April 09, 2018-- Delcath Systems, Inc., an interventional oncology company focused on the treatment of primary and metastatic liver cancers, announces that shareholders have approved the provisions ...

  • GlobeNewswire2 months ago

    Delcath’s PHP Therapy to be Featured in Video Training Session at European Conference of Interventional Oncology  

    NEW YORK, April 03, 2018-- Delcath Systems, Inc., an interventional oncology company focused on the treatment of primary and metastatic liver cancers, announces that Dr. Brian Steadman, Interventional ...

  • GlobeNewswire2 months ago

    Summary of Recent Published Research on Delcath’s PHP Therapy Presented at Society of Surgical Oncology Annual Symposia

    NEW YORK, March 29, 2018-- Delcath Systems, Inc., an interventional oncology company focused on the treatment of primary and metastatic liver cancers, announces that a comparative summary of recently published ...

  • GlobeNewswire2 months ago

    Delcath to Present at Oppenheimer 28th Annual Healthcare Conference

    NEW YORK, March 19, 2018-- Delcath Systems, Inc., an interventional oncology Company focused on the treatment of primary and metastatic liver cancers, announces that Jennifer K. Simpson, Ph.D., MSN, CRNP, ...

  • GlobeNewswire2 months ago

    Delcath Announces 2017 Financial Results

    NEW YORK, March 16, 2018-- Delcath Systems, Inc., an interventional oncology Company focused on the treatment of primary and metastatic liver cancers, announces financial results for the twelve months ...

  • GlobeNewswire2 months ago

    Delcath to Present at 30th Annual Roth Conference

    NEW YORK, March 12, 2018-- Delcath Systems, Inc., an interventional oncology Company focused on the treatment of primary and metastatic liver cancers, announces that Jennifer K. Simpson, Ph.D., MSN, CRNP, ...

  • OTCQX And OTCQB Companies to Present At 2018 ROTH Conference
    PR Newswire3 months ago

    OTCQX And OTCQB Companies to Present At 2018 ROTH Conference

    OTC Markets Group EVP Jason Paltrowitz to Speak on Panel on "Reg A+ Offerings" NEW YORK , March 8, 2018 /PRNewswire/ -- OTC Markets Group Inc.  (OTCQX: OTCM), operator of financial markets for ...

  • GlobeNewswire3 months ago

    Delcath Announces Commercial Supply Agreement for Melphalan Hydrochloride for Injection with Tillomed Laboratories

    NEW YORK, March 07, 2018-- Delcath Systems, Inc., an interventional oncology Company focused on the treatment of primary and metastatic liver cancers, announces it has entered into a commercial supply ...

  • ACCESSWIRE3 months ago

    Today's Research Reports on Stocks to Watch: Delcath and MGT Capital Investments

    NEW YORK, NY / ACCESSWIRE / February 20, 2018 / Latest key findings by Growth Market Report for all traders, shareholders, and investors of Delcath Systems, Inc. (OTCQB: DCTH) and MGT Capital Investments ...

  • ACCESSWIRE8 months ago

    Featured Company News - Delcath Systems Issues Letter to Stockholders; Attempts to Restore Access to Capital

    LONDON, UK / ACCESSWIRE / September 26, 2017 / Pro-Trader Daily takes a look at the latest corporate events and news making the headlines for Delcath Systems, Inc. (NASDAQ: DCTH ), following which we have ...